Amphastar Pharmaceuticals, Inc. (AMPH)
USD 24.1
(2.44%)
USD 24.1
(2.44%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 479.11 Million USD | 995.27% |
| 2022 | -53.51 Million USD | -146.73% |
| 2021 | -21.69 Million USD | 14.51% |
| 2020 | -25.37 Million USD | -259.38% |
| 2019 | -7.06 Million USD | 80.46% |
| 2018 | -36.12 Million USD | -95.92% |
| 2017 | -18.43 Million USD | 46.76% |
| 2016 | -34.63 Million USD | -38.67% |
| 2015 | -24.97 Million USD | -3.51% |
| 2014 | -24.12 Million USD | -12.67% |
| 2013 | -21.41 Million USD | -75.37% |
| 2012 | -12.21 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 425.73 Million USD | -11.14% |
| 2024 Q2 | 430.72 Million USD | 1.17% |
| 2023 Q2 | 380.14 Million USD | 609.65% |
| 2023 Q4 | 479.11 Million USD | 18.07% |
| 2023 FY | 479.11 Million USD | 995.27% |
| 2023 Q1 | -74.59 Million USD | -39.38% |
| 2023 Q3 | 405.77 Million USD | 6.74% |
| 2022 Q4 | -53.51 Million USD | 0.9% |
| 2022 Q3 | -54 Million USD | 13.22% |
| 2022 FY | -53.51 Million USD | -146.73% |
| 2022 Q1 | -67.35 Million USD | -210.52% |
| 2022 Q2 | -62.23 Million USD | 7.6% |
| 2021 Q3 | -474 Thousand USD | 98.79% |
| 2021 Q2 | -39.1 Million USD | -5.89% |
| 2021 Q1 | -36.92 Million USD | -45.55% |
| 2021 FY | -21.69 Million USD | 14.51% |
| 2021 Q4 | -21.69 Million USD | -4475.95% |
| 2020 Q2 | -22.68 Million USD | -293.28% |
| 2020 Q3 | -21.66 Million USD | 4.47% |
| 2020 Q4 | -25.37 Million USD | -17.1% |
| 2020 FY | -25.37 Million USD | -259.38% |
| 2020 Q1 | 11.73 Million USD | 266.2% |
| 2019 Q1 | -16.8 Million USD | 53.49% |
| 2019 FY | -7.06 Million USD | 80.46% |
| 2019 Q4 | -7.06 Million USD | 65.62% |
| 2019 Q3 | -20.53 Million USD | 61.37% |
| 2019 Q2 | -53.14 Million USD | -216.32% |
| 2018 Q1 | -8.78 Million USD | 52.38% |
| 2018 FY | -36.12 Million USD | -95.92% |
| 2018 Q4 | -36.12 Million USD | -106.0% |
| 2018 Q3 | -17.53 Million USD | -488.31% |
| 2018 Q2 | 4.51 Million USD | 151.44% |
| 2017 Q4 | -18.43 Million USD | 0.21% |
| 2017 FY | -18.43 Million USD | 46.76% |
| 2017 Q1 | -40.35 Million USD | -16.53% |
| 2017 Q2 | -36.23 Million USD | 10.22% |
| 2017 Q3 | -18.47 Million USD | 49.01% |
| 2016 Q1 | -23.06 Million USD | 7.66% |
| 2016 FY | -34.63 Million USD | -38.67% |
| 2016 Q4 | -34.63 Million USD | -44.94% |
| 2016 Q3 | -23.89 Million USD | 0.5% |
| 2016 Q2 | -24.01 Million USD | -4.12% |
| 2015 Q3 | -24.56 Million USD | 9.13% |
| 2015 Q2 | -27.03 Million USD | -34.02% |
| 2015 Q1 | -20.17 Million USD | 16.4% |
| 2015 FY | -24.97 Million USD | -3.51% |
| 2015 Q4 | -24.97 Million USD | -1.67% |
| 2014 Q4 | -24.12 Million USD | -12.06% |
| 2014 Q3 | -21.53 Million USD | -103.79% |
| 2014 Q2 | -10.56 Million USD | 0.65% |
| 2014 Q1 | -10.63 Million USD | 50.34% |
| 2014 FY | -24.12 Million USD | -12.67% |
| 2013 Q3 | -18.68 Million USD | 0.0% |
| 2013 Q4 | -21.41 Million USD | -14.63% |
| 2013 Q1 | 50.21 Million USD | 200.0% |
| 2013 FY | -21.41 Million USD | -75.37% |
| 2012 Q4 | -50.21 Million USD | 0.0% |
| 2012 FY | -12.21 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -25914.267% |
| Alpha Teknova, Inc. | 1.97 Million USD | -24171.074% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -408.573% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -539.241% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | -10.055% |
| Cosmos Health Inc. | 8.59 Million USD | -5477.052% |
| Journey Medical Corporation | -9.7 Million USD | 5034.71% |
| Embecta Corp. | 1.31 Billion USD | 63.482% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -4.45% |
| Dynavax Technologies Corporation | 106.63 Million USD | -349.3% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 466.212% |
| Pacira BioSciences, Inc. | 432.74 Million USD | -10.714% |
| PainReform Ltd. | -7.95 Million USD | 6126.553% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 3164.419% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 3164.419% |
| SCYNEXIS, Inc. | -19.35 Million USD | 2576.026% |
| Safety Shot Inc | -2.28 Million USD | 21073.395% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 5180.855% |
| Procaps Group, S.A. | 242.93 Million USD | -97.22% |
| Theratechnologies Inc. | 24.87 Million USD | -1826.384% |
| Harrow Health, Inc. | 116.41 Million USD | -311.547% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 19112.341% |
| Biofrontera Inc. | 4.05 Million USD | -11712.401% |
| DURECT Corporation | -7.65 Million USD | 6359.616% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 1529.03% |
| Cronos Group Inc. | -663.32 Million USD | 172.229% |
| OptiNose, Inc. | 58.06 Million USD | -725.129% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 23.144% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 3387.888% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 9338.491% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -3091.308% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 7633.611% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -448258.117% |
| Radius Health, Inc. | 359.28 Million USD | -33.353% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -242845.809% |
| ProPhase Labs, Inc. | 19.23 Million USD | -2391.347% |
| Phibro Animal Health Corporation | 454.84 Million USD | -5.335% |
| Procaps Group S.A. | 242.93 Million USD | -97.22% |
| Alvotech | 1.06 Billion USD | 54.984% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -12926.4% |
| Viatris Inc. | 17.13 Billion USD | 97.203% |
| Rockwell Medical, Inc. | 4.45 Million USD | -10652.042% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 9923.888% |
| SIGA Technologies, Inc. | -148.68 Million USD | 422.239% |
| Tilray Brands, Inc. | 158.97 Million USD | -201.371% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | -293.043% |
| Shineco, Inc. | 29.29 Million USD | -1535.732% |
| PetIQ, Inc. | 351.93 Million USD | -36.137% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 16612.938% |
| Incannex Healthcare Limited | -5.48 Million USD | 8834.932% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -170.226% |
| Alimera Sciences, Inc. | 55.3 Million USD | -766.244% |
| Silver Spike Investment Corp. | -32.61 Million USD | 1569.141% |
| Assertio Holdings, Inc. | -32.52 Million USD | 1572.873% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 32282.704% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 9567.878% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 10052.451% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 5933.23% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -11261.418% |
| Hempacco Co., Inc. | 13.61 Million USD | -3419.076% |
| Talphera, Inc. | -5.72 Million USD | 8474.602% |
| Alvotech | 1.06 Billion USD | 54.984% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -6605.542% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 595.41% |
| Currenc Group, Inc. | -16.57 Million USD | 2990.891% |
| Kamada Ltd. | -46.43 Million USD | 1131.866% |
| Indivior PLC | -33.95 Million USD | 1511.142% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -183767.539% |
| Flora Growth Corp. | -713 Thousand USD | 67296.494% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 5933.23% |
| Evolus, Inc. | 63.7 Million USD | -652.042% |
| HUTCHMED (China) Limited | -197.45 Million USD | 342.639% |
| Akanda Corp. | 3.9 Million USD | -12169.432% |